158 related articles for article (PubMed ID: 23913314)
21. A case of minimal change disease in a Fabry patient.
Zarate YA; Patterson L; Yin H; Hopkin RJ
Pediatr Nephrol; 2010 Mar; 25(3):553-6. PubMed ID: 19876652
[TBL] [Abstract][Full Text] [Related]
22. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
23. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
24. Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys.
Cybulla M; Schaefer E; Wendt S; Ling H; Kröber SM; Hövelborn U; Schandelmaier S; Rohrbach R; Neumann HP
Am J Kidney Dis; 2005 May; 45(5):e82-9. PubMed ID: 15861341
[TBL] [Abstract][Full Text] [Related]
25. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
[TBL] [Abstract][Full Text] [Related]
26. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
[TBL] [Abstract][Full Text] [Related]
28. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
29. Fabry Nephropathy: An Evidence-Based Narrative Review.
Del Pino M; Andrés A; Bernabéu AÁ; de Juan-Rivera J; Fernández E; de Dios García Díaz J; Hernández D; Luño J; Fernández IM; Paniagua J; Posada de la Paz M; Rodríguez-Pérez JC; Santamaría R; Torra R; Ambros JT; Vidau P; Torregrosa JV
Kidney Blood Press Res; 2018; 43(2):406-421. PubMed ID: 29558749
[TBL] [Abstract][Full Text] [Related]
30. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
[TBL] [Abstract][Full Text] [Related]
31. Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.
Sawada K; Mizoguchi K; Hishida A; Kaneko E; Koide Y; Nishimura K; Kimura M
Clin Nephrol; 1996 May; 45(5):289-94. PubMed ID: 8738659
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of Fabry disease and IgA nephropathy: a report of two cases.
Yin G; Wu Y; Zeng CH; Chen HP; Liu ZH
Ir J Med Sci; 2014 Dec; 183(4):671-5. PubMed ID: 24913738
[TBL] [Abstract][Full Text] [Related]
33. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
[TBL] [Abstract][Full Text] [Related]
34. New mutation in female patient with renal variant of Fabry disease and HIV.
Solis MA; Pascual B; Boscá M; Ramos V; Carda C; Monteagudo C; Torregrosa I; Pons S; Miguel A
J Nephrol; 2010; 23(2):231-3. PubMed ID: 20155722
[TBL] [Abstract][Full Text] [Related]
35. Identification of new α-galactosidase A mutation responsible for Fabry disease: A case report.
Battaglia Y; Scalia S; Rinaldi R; Storari A; Mignani R; Russo D; Duro G
Clin Nephrol; 2019 Feb; 91(2):126-128. PubMed ID: 30474596
[No Abstract] [Full Text] [Related]
36. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of Fabry disease with IgM nephropathy: A case report.
Wu H; Behera TR; Gong J; Shen Q
Medicine (Baltimore); 2019 Oct; 98(41):e17566. PubMed ID: 31593141
[TBL] [Abstract][Full Text] [Related]
38. A case of female Fabry disease revealed by renal biopsy.
Aratani S; Yamakawa H; Suzuki S; Otsuka T; Sakai Y; Shimizu A; Tsuruoka S
CEN Case Rep; 2020 Feb; 9(1):24-29. PubMed ID: 31542871
[TBL] [Abstract][Full Text] [Related]
39. Elevated globotriaosylsphingosine is a hallmark of Fabry disease.
Aerts JM; Groener JE; Kuiper S; Donker-Koopman WE; Strijland A; Ottenhoff R; van Roomen C; Mirzaian M; Wijburg FA; Linthorst GE; Vedder AC; Rombach SM; Cox-Brinkman J; Somerharju P; Boot RG; Hollak CE; Brady RO; Poorthuis BJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):2812-7. PubMed ID: 18287059
[TBL] [Abstract][Full Text] [Related]
40. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
